top of page
Mark Legare
Apr 11, 20235 min read
Portfolio Highlight - Our Investment in Voda.AI
Certain industries match well with certain founder profiles. A statement as equally true as it is banal. Within the vast domain ...
Matt Fates
Sep 21, 20224 min read
Why We Invested: Dyania Health
By Matt Fates, Partner at Innospark Ventures At any given time, there are roughly 400,000 clinical trials occurring globally. In the US,...
Matt Fates
Jul 7, 20223 min read
Why We Invested: ODAIA Intelligence
As skilled and advanced as the $2T pharma industry is in many regards, there are still key areas where it lags behind, and we believe...
bottom of page